The dramatic development of biomedical technologies inevitably raises a question of the increasing "gap" between basic biomedical discoveries and their use in clinical practice. Created in 1958 with the same purpose, DARPA has had to bridging the gap in defense technologies (mostly in rocket and radar sciences). Today we can talk about the relevance of the idea of "biomedical DARPA" (BioDARPA) as a concept of organizational design for priority research and development of emerging biotechnologies.
INTRODUCTION
Defense Advanced Research Projects Agency (DARPA) -the U.S. federal agency which mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming the American national security (Dugan and Gabriel, 2013; Munos, 2008) . The DARPA was created in response to Soviet Rocket Science Challenge in 1958, and up to now reconciles technological ambitions and hard reality (Klabukov et al., 2014) .
The ideas of realization of a darpa-like agency are formulated for microelectronics (Alic and Robyn, 1990) , energy (Bonvillian and van Atta, 2011) and since 1990 th also for biomedicine (Cook-Deegan, 1997) . This was especially critical for projects that were too radical for traditional institutions like the National Institutes of Health (NIH) and the National Science Foundation (NSF) (Marshall, 1997) .
Since early 2000 th biological projects have become the place in Agency programs (Eisenstadt, 2001 ) and the biomedical DARPA challenge was formulated (Greenberg, 2003) .
In 2014 the Agency created a new Biological Technology Office (BTO) to emphasized the new importance of biomedical technology (Laursen, 2014) and was allowed experts to talk about the phenomenon of "military-bioscience complex" (Reardon, 2015) . The office focuses on basic and applied research in the areas of gene editing, biotechnologies, neurosciences and synthetic biology -from powered exoskeletons for soldiers to brain implants that can control mental disorders (Reardon, 2015) . The BTO is responsible for all neurotechnology, humanmachine interface, human performance, infectious disease, and synthetic biology programs within the Agency.
CHALLENGES
In the 20 th century there were many challenges that stimulated the intensification of scientific and technical thought: the Manhattan Project, the Sputnik Challenge, the Apollo program. Among today's global challenges it's especially possible to distinguish the phenomena "colonization of space" and "immortality of the human". And if the first problem is still far from the full-scale embodiment, then the second one can be already formulated.
The Immortality of the Human project represents a complex problem which solution will demand permission of the whole group of technological tasks, many of which are listed in the collection of tasks in engineering biology (Klabukov, 2016) . Among the necessary for realization of concepts of technological decisions it is possible to note "life-like test-stand", "test-range for bioengineered devices", "pharmaceutical foundry in the Gut", "molecular scalpel for fetal and postnatal surgery in vivo" (Klabukov, 2017) , "biological Internet" (Klabukov, 2015) , "humanized animal models", "organ-on-chip for clinical trials", "bio-decks for human enhancement", etc.
Good example of transhumanistic challenges are presented in the Regenerative Medicine Roadmap 2.0 (Batin et al., 2010) and the Roadmap to Immortality (Fig. 1 ) (Batin et al., 2013) . 
DRIVERS

Political and Public activity
The industry has a very important social and business activity of individuals such as national security, and economic productivity and competitiveness through: 1) advancing areas of research at the intersection of the biological, physical, and information sciences and engineering;
2) supporting social science research that advances the field of engineering biology and contributes to the adoption of new products, processes, and technologies; 3) expanding the number of researchers, educators, and students with engineering biology training; 4) accelerating the translation and commercialization of engineering biology research and development by the private sector; 5) and improving the interagency planning and coordination of federal government activities related to engineering biology (Johnson, 2015) .
Professional communities and committees
Professional communities and committees are presented of the Standards Coordinating Body For Cellular/Gene and Regenerative Therapies and Cell-Based Drug Discovery (Hayakawa et al., 2016) , Synthetic Biology Open Language Developer's Group (Contreras et al., 2015) , iGEM Foundation (Shetty et al., 2008) , the NIST's public activity, Department of Defense workgroups, etc.
Public activities
The International movement for Life Extension has a bright and long-term history (Stambler, 2012) . Now the public movements are represented by various activities like the "Transhumanist party" by Zoltan Istvan (Lee, 2016) , Michael Batin's transhumanists community (Batin, 2015) , Dmitry Itskov's "2045 Initiative" (Petersen, 2015) , Craig Venter Institute's startups (Shimasaki, 2014) , KrioRus company (Bernstein, 2015) , etc.
ECONOMICS
The development of advanced technology sectors has always required the robust economic base like as long-term Pentagon contracts for microelectronics and radar technologies in Silicon Valley (Steinbock, 2014) In the field of advanced biomedical technologies can be used a government-supported leverage to research and market stimulation both the key directions and related fields (Fig. 2) .
ORGANIZATION MODEL
The previous attempts of realization of darpa-like models were implemented in the form of the government agencies (ARPA-E, i.e. Energy), the interrelated projects collaboration (HS-ARPA, i.e. homeland security), or even agency community (IARPA, i.e. intelligence).
Existing an experimental models of R&D activities like the CIA's venture funds "In-QTel" (Lerner et al., 2005) , "OnPoint Technologies" and other venture investment tools (Klabukov et al., 2012) . In many ways, these tools are made possible by M&A activity in the defense and aerospace sector in the mid-1990s.
In various discussions it was noted that technological development incentives could be:
1) funding mechanisms to support the early development phase of countermeasures (the "valley of death"); 2) creation of a "BioDARPA" that would invest in transformational bioresearch.
Such research would be "project driven" and linked to identified national needs ("Roundtable discussion : when terror strikes--preparing an effective and immediate public health response,"
2005).
▪ Development of shining-new Health and Wellness markets for personalized products ("markets for things that do not exist") (Connell, 2014) ;
▪ Establishment of a very early stage technology companies operates to creating future markets for things that do not exist (Connell, 2014) . For examples of this "companies of The hypothetical formation and location of "BioDARPA Concept" in the U.S.
Governance Innovation System are presented on Fig. 3 . Supposed that new business models (pharmaceutical industry framework) such as precompetitive research, crowdsourcing, networked innovation, virtual companies, drug repurposing, and forced disruption (e.g., DARPA) are spreading and enriching the biomedical innovation ecosystem (Munos and Orloff, 2016) .
The problem is noted that 90% of medical research stands to benefit only 10% of the population. While others dispute the numbers, there is little doubt that disparities exist in the global agenda for medical research (Mccarthy, 2015) . This bring up a point to accelerate the translation into clinical practice that can be achieved by experimental clinical sites. BioDARPA's Super-system (system-of-systems) complexity can be realized as mosaic exposome ("cloud model") around core organization system (Fig. 4) .
ETHICS
It's obviously that needing for liberation of biology to biotech revolution (Bailey, 2005) but influence of traditional conservative forces is for the present quite big. The studies in human enhancement and synthetic biology ethics are need to addition of new Responsible Research and Innovation (RRI) concepts (Nerlich and McLeod, 2016) . Further development of technologies for mass market production of organs in humanized animals edited using CRISPR/Cas9 system is associated with common models of "life" perception. It is necessary to overcome many more of ethical barriers (Fig. 5 ).
CONCLUSION
The BioDARPA Concept provides the advancing development and broadcasting in clinical practice of the advanced biomedical technologies. The problems of creation of this "firm" (or a cloud forms) are associated with the complexity of their constitution (system-ofsystems model), clear statement of the program goals (the White Book), source selection (both performers and consulting firms), staff recruitment, and location of the BioDARPA in the National Innovation System (both defense and civilian parts).
The ResearchGate Project Group "BioDARPA: Biomedical Breakthroughs and Superiority" † is founded for data collect discussing on actual themes ‡ .
